These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31016067)

  • 1. Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.
    Jilg S; Hauch RT; Kauschinger J; Buschhorn L; Odinius TO; Dill V; Müller-Thomas C; Herold T; Prodinger PM; Schmidt B; Hempel D; Bassermann F; Peschel C; Götze KS; Höckendorf U; Haferlach T; Jost PJ
    Exp Hematol Oncol; 2019; 8():9. PubMed ID: 31016067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Watts J; Lin TL; Mims A; Patel P; Lee C; Shahidzadeh A; Shami P; Cull E; Cogle CR; Wang E; Uckun FM
    Front Oncol; 2021; 11():806243. PubMed ID: 35096610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    El-Cheikh J; Bidaoui G; Saleh M; Moukalled N; Abou Dalle I; Bazarbachi A
    Clin Hematol Int; 2023 Jun; 5(2-3):143-154. PubMed ID: 37071328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf JP; Zeidan AM
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Pericole FV; Lazarini M; de Paiva LB; Duarte ADSS; Vieira Ferro KP; Niemann FS; Roversi FM; Olalla Saad ST
    Front Oncol; 2019; 9():16. PubMed ID: 30761268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia.
    Saliba AN; John AJ; Kaufmann SH
    Cancer Drug Resist; 2021; 4(1):125-142. PubMed ID: 33796823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
    Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomethylating agents after allogeneic blood stem cell transplantation.
    Schroeder T; Rautenberg C; Haas R; Kobbe G
    Stem Cell Investig; 2016; 3():84. PubMed ID: 28066786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment.
    Li Z; Wang J; Ge SS; Qiu QC; Du JH; Shan SS; Shen XD; Wan CL; Wang BR; Wu DP; Qiu HY; Xue SL
    Front Oncol; 2022; 12():841276. PubMed ID: 35211416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
    Levitz D; Saunthararajah Y; Fedorov K; Shapiro LC; Mantzaris I; Shastri A; Kornblum N; Sica RA; Shah N; Konopleva M; Gritsman K; Braunschweig I; Cooper DL; Pradhan K; Verma A; Feldman EJ; Goldfinger M
    Clin Cancer Res; 2023 Aug; 29(15):2774-2780. PubMed ID: 37341641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatment options for patients with high-risk myelodysplastic syndrome.
    Bewersdorf JP; Carraway H; Prebet T
    Ther Adv Hematol; 2020; 11():2040620720955006. PubMed ID: 33240476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
    Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A
    Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
    Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
    Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax.
    Jehangir W; Karabachev A; Jahangir T; Umyarova E
    Case Rep Hematol; 2020; 2020():9031067. PubMed ID: 32231817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C; Schuster T; Peschel C; Götze KS
    Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.